Johnson & Johnson has signed a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotech firm developing oral targeted therapies for solid tumors through its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The all-cash deal is valued at USD 3.05 billion and is expected to close in the coming months, pending antitrust approval and other customary conditions.
Halda’s leading candidate, HLD-0915, is an investigational once-daily therapy for prostate cancer a disease expected to see 1.7 million new cases worldwide by 2030. The therapy aims to address resistance to existing treatments and improve patient outcomes. The acquisition also brings Halda’s early-stage programs targeting breast, lung, and several other tumour types, with potential applications beyond oncology.
“This acquisition bolsters our oncology pipeline with a promising prostate cancer asset and a platform capable of addressing multiple cancers and diseases,” said Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson. “We look forward to integrating Halda’s expertise with our R&D, commercial and manufacturing strengths to deliver these therapies globally.
John C. Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, R&D at J&J, highlighted that Halda’s technology is uniquely designed to overcome treatment resistance. Early data for HLD-0915 show strong preliminary efficacy and safety. We are excited to expedite the ongoing Phase 1/2 trial and advance additional RIPTAC-based candidates.
J&J expects the acquisition to result in a $0.15 dilution to Adjusted EPS in 2026 due to short-term financing costs and a one-time charge related to equity awards for Halda employees. The company will share full-year 2026 guidance during its fourth-quarter earnings call on January 21, 2026.
